Ask AI
ProCE Banner Activity

Interactive Decision Support Tool: Expert Treatment Guidance for HER2-Positive Metastatic Breast Cancer

Tool

Access this Interactive Decision Support Tool on selecting optimal therapy for patients HER2-positive metastatic breast cancer and learn from the experts about their key decision-making criteria and other key considerations.

Released: July 24, 2025

Expiration: January 23, 2026

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Smart Patients

ProCE Banner

Disclosure

Primary Author

Shipra Gandhi, MD, MS: consultant/advisor/speaker: AstraZeneca, Hologic, Novartis, Roche.

Reshma Mahtani, DO: consultant/advisor: Agendia, AstraZeneca, Arvinas, Bicycle Therapeutics, Daiichi Sankyo, Genentech, Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, Stemline.

Erica L. Mayer, MD, MPH, FASCO: consultant/advisor/speaker: AstraZeneca, Lilly, Novartis.

Heather McArthur, MD, MPH, FASCO: consultant/advisor/speaker: ALX, AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Merck, Novartis, Pfizer, Stemline.

Laura Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Precede, Seagen; researcher: AstraZeneca, Genentech, Gilead, Lilly, Merck; other (travel support): Lilly.